Fjarde AP Fonden Fourth Swedish National Pension Fund Decreases Stock Holdings in Kenvue Inc. (NYSE:KVUE)

Fjarde AP Fonden Fourth Swedish National Pension Fund reduced its holdings in Kenvue Inc. (NYSE:KVUE) by 6.3% in the fourth quarter, HoldingsChannel.com reports. The institutional investor owned 479,632 shares of the company’s stock after selling 32,400 shares during the period. Fjarde AP Fonden Fourth Swedish National Pension Fund’s holdings in Kenvue were worth $10,240,000 at the end of the most recent reporting period.

A number of other large investors have also recently made changes to their positions in KVUE. Huntington National Bank lifted its holdings in shares of Kenvue by 26.5% in the 3rd quarter. Huntington National Bank now owns 4,161 shares of the company’s stock valued at $96,000 after acquiring an additional 871 shares during the last quarter. ING Groep NV raised its position in Kenvue by 23.6% during the third quarter. ING Groep NV now owns 3,576,616 shares of the company’s stock valued at $82,727,000 after purchasing an additional 681,954 shares during the period. Handelsbanken Fonder AB lifted its stake in shares of Kenvue by 2.9% in the 4th quarter. Handelsbanken Fonder AB now owns 742,184 shares of the company’s stock valued at $15,846,000 after purchasing an additional 21,222 shares during the last quarter. Alberta Investment Management Corp lifted its stake in shares of Kenvue by 23.2% in the 4th quarter. Alberta Investment Management Corp now owns 582,895 shares of the company’s stock valued at $12,445,000 after purchasing an additional 109,700 shares during the last quarter. Finally, Empower Advisory Group LLC bought a new stake in Kenvue in the fourth quarter worth $48,252,000. 97.64% of the stock is currently owned by institutional investors.

Kenvue Trading Up 4.1 %

KVUE opened at $23.31 on Monday. The company has a quick ratio of 0.69, a current ratio of 1.00 and a debt-to-equity ratio of 0.66. The stock’s fifty day moving average is $21.31 and its two-hundred day moving average is $22.20. The company has a market capitalization of $44.68 billion, a P/E ratio of 43.97, a PEG ratio of 2.62 and a beta of 1.45. Kenvue Inc. has a 52 week low of $17.67 and a 52 week high of $24.46.

Kenvue (NYSE:KVUE) last announced its quarterly earnings results on Thursday, February 6th. The company reported $0.26 EPS for the quarter, meeting the consensus estimate of $0.26. Kenvue had a return on equity of 20.97% and a net margin of 6.66%. Analysts forecast that Kenvue Inc. will post 1.14 earnings per share for the current year.

Kenvue Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Wednesday, February 26th. Stockholders of record on Wednesday, February 12th will be issued a $0.205 dividend. The ex-dividend date of this dividend is Wednesday, February 12th. This represents a $0.82 annualized dividend and a dividend yield of 3.52%. Kenvue’s dividend payout ratio is currently 154.72%.

Wall Street Analysts Forecast Growth

A number of research firms have weighed in on KVUE. Deutsche Bank Aktiengesellschaft cut shares of Kenvue from a “buy” rating to a “hold” rating and cut their price objective for the company from $25.00 to $24.00 in a research report on Thursday, December 12th. Royal Bank of Canada reiterated a “sector perform” rating and set a $24.00 price target on shares of Kenvue in a report on Monday, February 3rd. Barclays decreased their price objective on shares of Kenvue from $23.00 to $21.00 and set an “equal weight” rating for the company in a research note on Friday, January 17th. Citigroup cut their target price on Kenvue from $25.00 to $21.00 and set a “neutral” rating on the stock in a research note on Wednesday, January 15th. Finally, Piper Sandler raised Kenvue from a “neutral” rating to an “overweight” rating and raised their price target for the stock from $21.00 to $26.00 in a research note on Monday, January 6th. One equities research analyst has rated the stock with a sell rating, eight have given a hold rating and five have given a buy rating to the company’s stock. Based on data from MarketBeat.com, Kenvue has an average rating of “Hold” and an average price target of $23.00.

Kenvue Profile

Kenvue Inc operates as a consumer health company worldwide. The company operates through three segments: Self Care, Skin Health and Beauty, and Essential Health. The Self Care segment offers cough, cold and allergy, pain care, digestive health, smoking cessation, eye care, and other products under the Tylenol, Motrin, Benadryl, Nicorette, Zarbee's, ORSLTM, Rhinocort, Calpol, and Zyrtec brands.